(Press-News.org) First meta-analysis to look at quality of safety reporting in published reports of clinical trials of the drug finasteride for male pattern baldness
Zero of 34 clinical trials had adequate safety reporting
Available toxicity information in published reports of clinical trials is very limited, of poor quality and appears systematically biased
CHICAGO --- Published reports of clinical trials provide insufficient information to adequately establish the safety of finasteride for treatment of hair loss in men, according to a new Northwestern Medicine study to be published April 1 in JAMA Dermatology.
This study is the first meta-analysis of the quality of safety reporting in clinical trials of finasteride for treatment of male hair loss.
Finasteride blocks 5α-reductase in the scalp and male reproductive organs, inhibiting the conversion of the male hormone testosterone to its more potent form, 5α-dihydrotestosterone (5α- DHT). Men who take finasteride experience a 70 percent reduction in the amount of 5α-DHT in their blood.
Not one of the 34 published clinical trial reports provided adequate information about the severity, frequency or reversibility of sexual adverse effects. (Adequate quality of adverse event reporting requires using an explicit toxicity scale to grade adverse event severity and reported numbers and/or rates of occurrence for each specific type of adverse event per study arm.)
The published clinical trial reports did not answer the key questions doctors and patients want to know:
1) How safe is finasteride? Specifically, what is the risk that a man taking finasteride will develop sexual dysfunction?
2) How severe is finasteride-associated sexual dysfunction when it happens to a man?
3) If a man gets sexual dysfunction while taking finasteride, will sexual function return to normal when the drug is stopped? What is the risk of persistent sexual dysfunction associated with taking finasteride?
Finasteride was originally developed to treat enlarged prostate (prostatic hyperplasia) in older men. Men who take the drug for male pattern hair loss are typically younger and take a dose of finasteride that is about one-fifth the dose used for prostatic hyperplasia.
"People who take or prescribe the drug assume it's safe, but there is insufficient information to make that judgment," said lead study author Dr. Steven Belknap, research assistant professor of dermatology and general internal medicine at Northwestern University Feinberg School of Medicine.
"Our findings raise several questions," Belknap said. "Why do the published reports of these 34 clinical trials not provide adequate information about the severity and frequency of sexual toxicity? Was this information obtained but then not included in published articles? Or, were these clinical trials performed in a way that simply didn't capture this essential information? And most importantly, is the risk to benefit ratio of finasteride acceptable?"
The study is a report from the RADAR (Research on Adverse Drug Events and Reports) project at Northwestern's Feinberg School. The RADAR study points to a larger problem in the way clinical trials are performed and analyzed in meta-analyses.
"Typically, there is more focus on the desirable effects of the drug being studied compared to the toxic effects," Belknap said.
Among other key findings of the paper:
Of 5,704 men in the Northwestern Medicine clinical data repository who were treated for male pattern baldness with finasteride, only 31 percent would meet inclusion criteria for the pivotal trials referenced in the manufacturer's "Full Prescribing Information."
Thus, the available information from clinical trials does not apply to most of these men in Northwestern's study population who took finasteride for male pattern baldness. For example, some men with hair loss who are taking finasteride have diabetes mellitus, high blood pressure or are taking other drugs such as diuretics or antidepressants that also increase the risk of sexual dysfunction.
Duration of drug safety evaluation was limited to one year or less for 26 of 34 trials (76 percent.) But 33 percent of men in the Northwestern clinical data repository took finasteride for more than one year.
INFORMATION:
Other Northwestern authors on the study are senior author Dr. Dennis West, Imran Aslam, Tina Kiguradze, William H. Temps, John Cashy, Dr. Robert E. Brannigan and Dr. Beatrice Nardone.
The study was funded by 5R01CA102713-04 and 1R01 CA125077-01A1 from the National Cancer Institute of the National Institutes of Health. Additional funding was provided by the Post-Finasteride Syndrome Foundation.
NORTHWESTERN NEWS: http://www.northwestern.edu/newscenter/
Those suffering from depressive symptoms have an increased risk for physical diseases, especially for arthrosis and arthritis. These findings were reported by researchers from the University of Basel and the Ruhr-University Bochum. Their results, based on data from 14,300 people living in Switzerland, have been published in the scientific journal "Frontiers in Public Health".
Depression is one of the leading health risks and affects 350 million people worldwide. In Switzerland, around 400,000 people individuals suffer from it each year. Several studies in countries around ...
For the crew of the Starship Enterprise, Star Trek's "Tricorder" was an essential tool, a multifunctional hand-held device used to sense, compute, and record data in a threatening and unpredictable universe. It simplified a number of Starfleet tasks, scientific or combat-related, by beaming sensors at objects to obtain instant results.
The Tricorder is no longer science fiction. An invention by Tel Aviv University researchers may be able to turn smartphones into powerful hyperspectral sensors, capable of identifying the chemical components of objects from a distance. ...
Low doses of the anti-cancer drug imatinib can spur the bone marrow to produce more innate immune cells to fight against bacterial infections, Emory researchers have found.
The results were published March 30, 2015 in the journal PLOS Pathogens.
The findings suggest imatinib, known commercially as Gleevec , or related drugs could help doctors treat a wide variety of infections, including those that are resistant to antibiotics, or in patients who have weakened immune systems. The research was performed in mice and on human bone marrow cells in vitro, but provides information ...
COLUMBIA, Mo. - A drug used for decades to treat leukemia may have other uses in the fight against cancer, researchers at the University of Missouri have found. Previously, doctors used 6-Thioguanine, or 6-TG, as a chemotherapy treatment to kill cancer cells in patients with leukemia. In recent years, many doctors have shelved 6-TG in exchange for newer drugs that are more effective. Now, Jeffrey Bryan, an associate professor of oncology at the MU College of Veterinary Medicine, and his colleagues found that 6-TG can not only kill cancer cells, but also works to change ...
College students may realize that texting in the shower or at a funeral is inappropriate, but many do it anyway, according to Penn State psychologists.
"We have looked at inappropriate texting behavior -- texting while driving, for instance -- before, but what we wanted to find out is whether the people who are engaging in these forms of behavior even know whether or not it is the right thing to do," said Marissa Harrison, associate professor of psychology, Penn State Harrisburg.
The researchers suggest that college students are not necessarily trying to create new ...
Why It's Not Time for Health Care Rationing
Peter A. Ubel
There is a notable change in professional debates about how to better control health care costs. Discussion of health care rationing has become much more muted. "I contend that debates about health care rationing have waned not because the need to ration has dwindled nor because ethical debates about how or whether to ration have been resolved," writes Peter A. Ubel. They have declined because the word "rationing" has been replaced by terms such as "value" that "are not burdened by emotional and historical baggage." ...
DETROIT - A new study by scientists at the Wayne State University School of Medicine demonstrates that communication between some of the brain's most important centers is altered in children with obsessive-compulsive disorder.
The research led by the Department of Psychiatry and Behavioral Neuroscience's David Rosenberg, M.D., and Vaibhav Diwadkar, Ph.D., sheds significant light on our understanding of how brain networks contribute to obsessive-compulsive disorder in youth.
The study included youth with a diagnosis of OCD and a comparison group free of psychiatric illness. ...
A Chemistry undergraduate at the University of York has helped to develop a new drug release gel, which may help avoid some of the side effects of painkillers such as ibuprofen and naproxen.
In a final year project, MChem undergraduate student Edward Howe, working in Professor David Smith's research team in the Department of Chemistry at York looked for a way of eliminating the adverse side-effects associated pain-killing drugs, particularly in the stomach, and the problems, such as ulceration, this could cause patients.
Supervised by PhD student Babatunde Okesola, whose ...
Andres Pinto, an orofacial pain and oral medicine specialist at Case Western Reserve University School of Dental Medicine, often feels like the doctor in the television series House, who solves medical mysteries each week.
Pinto is among about 700 facial pain and oral medicine specialists nationally who patients often turn to when their own doctors are unable to identify and treat complex and rare medical conditions. In fact, according to a new study Pinto conducted with input from fellow members of the American Academy of Oral Medicine (AAOM), patients see, on average, ...
A small area in the midbrain known as the substantia nigra is the control center for all bodily movement. Increasing loss of dopamine-generating neurons in this part of the brain therefore leads to the main symptoms of Parkinson's disease - slowness of movement, rigidity and shaking.
In recent years, there has been increasing scientific evidence suggesting that inflammatory changes in the brain play a major role in Parkinson's. So far, it has been largely unclear whether this inflammation arises inside the brain itself or whether cells of the innate immune system that ...
